Every 8-K that Apogee Therapeutics Inc (APGE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow APGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APGE filings page.
Apogee Therapeutics, Inc. (APGE) completed its sale to AbbVie Inc. on September 3, 2026, when Andor Merger Co., an AbbVie subsidiary, merged with Apogee, leaving Apogee as a wholly owned subsidiary of Andor LLC. The total equity value of the transaction was approximately $10.9 billion, funded by AbbVie with a combination of cash on hand and debt. Each share of Apogee common stock outstanding immediately before the effective time was converted into the right to receive the merger consideration, and former stockholders now hold only that right.
Apogee notified the Nasdaq Global Market of the merger, requested filing of a Form 25 to delist and deregister its common stock under Section 12(b), and plans to file Form 15 to terminate registration under Section 12(g) and suspend reporting obligations. Trading in APGE will be suspended on September 4, 2026. As a result of the merger, a change in control occurred and Apogee became an indirect wholly owned subsidiary of AbbVie. All Apogee directors resigned at the effective time and were replaced by the former Merger Sub directors, and all executive officers ceased serving. Apogee also terminated its 2023 Equity Incentive Plan and 2023 Employee Stock Purchase Plan and adopted amended and restated charter documents. Agreements provide for limited gross-up payments for excise taxes on parachute payments, capped at $12.5 million in aggregate.
Apogee Therapeutics, Inc. reported results of a special stockholder meeting relating to its planned merger with AbbVie. Under a previously announced Merger Agreement, a subsidiary of AbbVie will merge with Apogee, with Apogee surviving as an indirect wholly owned subsidiary of AbbVie.
As of the July 10, 2026 record date, 62,140,183 shares of Apogee voting common stock were outstanding, and 46,526,253 shares (about 74.87%) were present at the August 11, 2026 special meeting. Stockholders approved the Merger Proposal, casting 46,508,107 votes for, 3,885 against, and 14,261 abstentions, which, together with the written consent of all holders of non-voting common stock, satisfies one closing condition for the merger.
Stockholders did not approve, on a non-binding, advisory basis, the Compensation Proposal related to merger-linked payments to named executive officers; however, this advisory vote is not a condition to closing. An Adjournment Proposal was not needed and was not voted upon. In connection with the anticipated merger closing, all current Apogee directors have indicated they will resign at the effective time, and the company states these anticipated resignations are not due to any disagreement over operations, policies or practices.
Apogee Therapeutics is being acquired by AbbVie under a definitive agreement in which AbbVie will purchase all outstanding Apogee shares for $135.11 per share in cash, implying total equity value of approximately $10.9 billion. Closing is targeted for the third quarter of 2026, subject to stockholder and regulatory approvals and other customary conditions.
Apogee reported positive 16‑week Phase 2 APEX Part B results for zumilokibart in moderate‑to‑severe atopic dermatitis, meeting all primary and secondary endpoints with mid‑dose patients achieving 65.9% EASI‑75 and statistically significant benefits across multiple skin and symptom measures. Based on these data, the company plans to advance zumilokibart into Phase 3 this year and to initiate additional trials in eosinophilic esophagitis in 2H 2026 and asthma in 1H 2027.
Apogee also entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non‑dilutive capital. As of June 30, 2026, cash, cash equivalents and securities totaled $1.3 billion. For the quarter, Apogee recorded a net loss of $85.9 million, with higher research and development and general and administrative expenses, including merger transaction costs.
Apogee Therapeutics agreed to be acquired by AbbVie in an all-cash deal. AbbVie will buy all outstanding Apogee shares for $135.11 per share, valuing Apogee at about $10.9 billion, with Apogee becoming a wholly owned AbbVie subsidiary.
The merger, executed via AbbVie subsidiaries Andor LLC and Andor Merger Co., is unanimously approved by both boards and expected to close in the third quarter of 2026, subject to Apogee stockholder and regulatory approvals and the absence of legal blocks. The transaction has no financing condition, and AbbVie guarantees its subsidiaries’ obligations.
The merger agreement includes reciprocal termination fees of $381,273,716 in specified circumstances, including failed regulatory approvals or Apogee accepting a superior offer. Key Apogee holders have signed a voting agreement to support the deal. AbbVie highlights Apogee’s immunology pipeline, led by zumilokibart (APG777) for atopic dermatitis and asthma and the APG273 combination program, as strategic drivers of the acquisition.
Apogee Therapeutics, Inc. entered into two agreements with Paragon Therapeutics focused on discovering and developing antibodies targeting the IL-31 receptor (IL-31R). Under an antibody discovery agreement, Paragon will generate and characterize monospecific IL-31R antibody candidates, with Apogee paying research fees and reimbursing certain outsourced costs. Optional CMC activities would trigger additional fees between $1.3 million and $2.0 million, depending on scope.
Through a separate IL-31R license agreement, Apogee received an exclusive, worldwide, royalty-bearing, sublicensable license to IL-31R-directed antibodies discovered under the discovery agreement, while Paragon retained non-exclusive rights for multispecific antibodies. Apogee may owe up to $23.25 million in development, clinical and regulatory milestones for the first qualifying product, including $5.25 million upon first dosing in a Phase I human trial, plus low-single digit royalties on net sales during a defined royalty term. Both agreements include standard termination rights for convenience, breach and insolvency.
Apogee Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Shareholders elected three Class III directors — Mark C. McKenna, Jennifer Fox, and William (BJ) Jones, Jr. — to serve until the 2029 Annual Meeting.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. There were 61,853,254 shares of voting common stock entitled to vote as of the April 15, 2026 record date.
Apogee Therapeutics entered a major financing collaboration with Blackstone Life Sciences built around future sales of its anti‑IL‑13 antibody zumilokibart. Under a new revenue participation right agreement, Apogee receives an upfront $100.0 million now, with the potential for additional tranches of $100.0 million, $200.0 million, and $250.0–$400.0 million tied to Phase 3 enrollment, positive Phase 3 results, and U.S. marketing approval by December 31, 2030.
The revenue share runs for 15 years from first approval, with tiered percentages on annual global zumilokibart sales. For Tier 1 sales up to $5 billion, the maximum combined revenue share can reach 3.4375%, declining at higher sales levels and subject to a $1.0 billion cap on Tranche 4‑related payments. Apogee and Blackstone also agreed to negotiate up to $500.0 million in senior debt.
Combined with Apogee’s existing $1.3 billion cash balance, management highlights up to $1.3 billion in flexible, largely non‑dilutive capital that it believes can support Phase 3 development and potential commercialization of zumilokibart. Following this deal, Apogee withdrew its prior cash runway end‑date guidance.
Apogee Therapeutics reported positive 16-week Part B results from its Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis. The study met all primary and secondary endpoints with high statistical significance, including 65.9% of mid-dose patients achieving EASI-75, a 41.9% placebo-adjusted improvement. Zumilokibart was well tolerated with a safety profile consistent with other drugs in its class. Based on these data and prior Part A maintenance results, Apogee plans to advance the mid-dose into Phase 3 AD trials in the second half of 2026 and has outlined additional trials in asthma and eosinophilic esophagitis. The company also announced a strategic financing collaboration with Blackstone Life Sciences expected to fund development through potential commercialization of zumilokibart in AD, asthma, and EoE.
Apogee Therapeutics reported a larger net loss but strong cash position for the first quarter of 2026 while highlighting significant pipeline progress. Net loss was $74.1 million for the quarter ended March 31, 2026, compared with $55.3 million a year earlier, driven by higher R&D and G&A spending.
R&D expenses rose to $60.8 million from $46.4 million, and G&A expenses increased to $22.0 million from $16.7 million, reflecting expansion of zumilokibart and combination programs and higher personnel costs. Cash, cash equivalents, marketable securities and long‑term marketable securities totaled $1.3 billion as of March 31, 2026, up from $902.9 million on December 31, 2025, supported by an upsized public equity offering with approximately $403 million in gross proceeds.
The company reported strong 52‑week Phase 2 APEX Part A data for zumilokibart in atopic dermatitis, with high maintenance of EASI‑75 and IGA 0/1 responses on 3‑ and 6‑month dosing, and plans to start Phase 3 trials in the second half of 2026. Interim positive Phase 1b asthma results, advancing combination assets APG279 and APG273, and a stated cash runway into 2029 underpin plans to pursue a future BLA filing for zumilokibart in atopic dermatitis.
Apogee Therapeutics, Inc. reported that two directors, Andrew Gottesdiener, M.D. and Peter Harwin, have notified the Board of their intention to resign effective May 11, 2026. The company states these resignations are not due to any disagreement regarding its operations, policies or practices.
Following their departure, the size of the Board will be reduced from nine directors to seven directors, consolidating governance among a smaller group of board members.
Apogee Therapeutics, Inc. entered an underwriting agreement to issue and sell 5,000,000 shares of common stock at $70.00 per share. Underwriters were granted a 30-day option to buy up to 750,000 additional shares, which was exercised in full on March 25, 2026.
Net proceeds from the offering, including the exercised option, are expected to be approximately $377.4 million after underwriting discounts, commissions and estimated expenses. The transaction is being conducted under an existing shelf registration statement, with a final prospectus supplement filed on March 25, 2026, and is expected to close on March 26, 2026.
Apogee Therapeutics reported positive 52-week maintenance results from Part A of its Phase 2 APEX trial of zumilokibart (APG777) in moderate-to-severe atopic dermatitis. At 3- and 6‑month dosing intervals, 75% and 85% of patients maintained EASI‑75, and 86% and 78% maintained vIGA 0/1, showing durable disease control with infrequent injections.
The 360 mg subcutaneous regimen produced deepening responses across lesion and itch endpoints in both initial 16‑week responders and the full treated population, with a safety profile generally in line with other agents in the class. APEX Part B, a 347‑patient, placebo‑controlled dose‑optimization study, is expected to deliver 16‑week data in the second quarter of 2026.
Based on these data and the anticipated Part B induction results, the company plans to start Phase 3 trials in the second half of 2026, targeting a potential commercial launch in 2029 in what it believes could be a $50 billion atopic dermatitis market.
Apogee Therapeutics reported a larger full-year 2025 net loss of $255.8 million, up from $182.1 million in 2024, as it increased investment in its pipeline. Research and development expenses rose to $214.7 million and general and administrative expenses to $70.9 million.
The company ended 2025 with cash, cash equivalents and marketable securities totaling $902.9 million, and it believes this will fund operations into the second half of 2028. Key zurmilokibart (APG777) milestones include APEX Phase 2 Part A 52-week data expected in March, Part B data in Q2 2026, and Phase 3 initiation in atopic dermatitis in the second half of 2026, alongside a head-to-head APG279 trial versus DUPIXENT with results expected in the second half of 2026.
Apogee Therapeutics, Inc. reports positive interim Phase 1b data for its anti-IL-13 antibody zumilokibart (APG777) in adults with mild-to-moderate asthma. The double-blind, placebo-controlled study enrolled 31 patients randomized 3:1 to a single 720 mg dose of zumilokibart or placebo, and included a key analysis set of 19 patients with elevated FeNO, a biomarker of Type 2 inflammation. The company also noted observed improvements in asthma and sinusitis symptom scores in its APEX Phase 2 Part A atopic dermatitis trial and highlighted additional data readouts and milestones expected in 2026. Apogee stated it believes it has cash runway into the second half of 2028.
Apogee Therapeutics (APGE) furnished an 8‑K noting two updates. The company issued an earnings press release covering the quarter ended September 30, 2025, and separately announced positive interim Phase 1 results from a healthy volunteer trial of APG333.
The earnings release is furnished as Exhibit 99.1 and the clinical data release as Exhibit 99.2. Both exhibits are furnished, not filed, under the Exchange Act.
Apogee Therapeutics, Inc. entered into an underwriting agreement to sell 6,951,221 shares of common stock at $41.00 per share and pre-funded warrants for 365,853 shares at $40.99999 per warrant in a public offering. The company also granted underwriters a 30-day option to buy up to 1,097,561 additional common shares, which was exercised in full, and expects net proceeds of approximately $323.3 million after fees and expenses. The securities are being issued off an effective shelf registration, with closing expected on October 10, 2025. Apogee also updated clinical timelines, now planning to enroll 320 patients and complete enrollment in Part B of its APEX Phase 2 APG777 atopic dermatitis trial by year-end, with topline maintenance data from Part A expected in the first quarter of 2026, Part B 16-week induction data in the second quarter of 2026, and Phase 1b APG777 asthma topline data in the first quarter of 2026.
Apogee Therapeutics, Inc. furnished an earnings press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to this Current Report as Exhibit 99.1, and a Cover Page Interactive Data File is provided as Exhibit 104.
The filing states that the exhibit furnished under Item 2.02 is not deemed to be "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. The registrant is Apogee Therapeutics, Inc., incorporated in Delaware, trading on the Nasdaq Global Market under the symbol APGE.
Apogee Therapeutics (APGE) filed an 8-K to disclose positive 16-week data from Part A of its Phase 2 APEX trial evaluating APG777, an anti-IL-13 antibody, in moderate-to-severe atopic dermatitis (AD). The randomized, placebo-controlled study (n = 123; 2:1 randomization) met its primary endpoint, delivering a 71.0% mean EASI score reduction versus 33.8% for placebo. Key secondary endpoints also favored APG777, with EASI-75 achieved by 66.9% of treated patients (24.6% placebo) and EASI-90 by 33.9% (14.7% placebo). Exposure-response analyses showed up to 89.5% EASI-75 in the highest drug-exposure quartile.
Safety appeared benign: TEAEs occurred in 56.1% of treated subjects versus 63.4% placebo, serious TEAEs were 1.2% vs 2.4%, and no injection-site reactions were reported. Common events—non-infective conjunctivitis, URTI, nasopharyngitis—were comparable or lower than placebo.
Next steps: Part B (≈280 pts, four-arm dose optimisation) is enrolling with 16-week data expected mid-2026, enabling a planned Phase 3 start in 2026. Maintenance data (3-/6-month dosing) from Part A are due 1H 2026. A separate Phase 1b head-to-head trial of APG279 versus Dupixent has begun, with readout 2H 2026.
The company will host a conference call on 7 July 2025 at 8:00 a.m. ET to review results. Exhibits 99.1 and 99.2 contain the full press release and deck; they are furnished, not filed.
On 17 June 2025 Apogee Therapeutics, Inc. (Nasdaq: APGE) held its 2025 Annual Meeting of Stockholders. Shareholders elected three Class II directors—Dr Lisa Bollinger (35.1 M votes for), Tomas Kiselak (39.2 M) and Nimish Shah (25.8 M)—to serve until the 2028 meeting; abstentions ranged from 0.2 M to 13.6 M and 1.8 M broker non-votes were recorded for each nominee.
Ernst & Young LLP was ratified as independent auditor for fiscal 2025 with 41.16 M votes in favor (99.9%), 3,099 against and 26,229 abstentions.
In the non-binding vote on the frequency of future “say-on-pay” proposals, a decisive 39.35 M shares (≈99%) supported annual advisory votes; the Board will adopt this cadence going forward.
No financial results, strategic transactions or other material events were disclosed. The filing is routine corporate-governance housekeeping and is unlikely to affect the company’s valuation or near-term outlook.